天风证券完成国有控股后 营收净利双增 市值翻倍

Group 1 - He Yuan Bio, a star company innovating in "rice blood-making" technology, recently went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with its market value increasing from 60 million to over 30 billion, a growth of over 500 times over 15 years [1] - Tianfeng Securities has been a significant capital force behind He Yuan Bio, participating in its angel round investment in 2010 and further investing in its Pre-IPO round in 2022, demonstrating long-term support [3] - In 2023, Hubei Hongtai Group became the controlling shareholder of Tianfeng Securities, filling a gap in provincial state-owned capital controlling brokerages and stabilizing local finance [3] Group 2 - Tianfeng Securities reported a cumulative operating income of 2.112 billion yuan from January to September 2023, a year-on-year increase of 57.53%, and achieved a net profit of 153 million yuan, marking a turnaround from losses [3] - The total market value of Tianfeng Securities reached 59.23 billion yuan by the end of October 2023, an increase of 27.57 billion yuan since Hubei Hongtai Group took control in March 2023, moving its market ranking from 16th to 5th among A-share listed companies in Hubei [3] - Tianfeng Securities has facilitated nearly 930 billion yuan in financing for the real economy over the past three years, with approximately 120 billion yuan directed towards Hubei enterprises [4]